MA52680A1 - Méthodes de réduction du besoin de revascularisation artérielle périphérique chez un sujet traité par des statines - Google Patents

Méthodes de réduction du besoin de revascularisation artérielle périphérique chez un sujet traité par des statines

Info

Publication number
MA52680A1
MA52680A1 MA52680A MA52680A MA52680A1 MA 52680 A1 MA52680 A1 MA 52680A1 MA 52680 A MA52680 A MA 52680A MA 52680 A MA52680 A MA 52680A MA 52680 A1 MA52680 A1 MA 52680A1
Authority
MA
Morocco
Prior art keywords
need
peripheral arterial
reducing
methods
statins
Prior art date
Application number
MA52680A
Other languages
English (en)
Inventor
Craig Granowitz
Sephy Philip
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Pharmaceuticals Ie Ltd filed Critical Amarin Pharmaceuticals Ie Ltd
Publication of MA52680A1 publication Critical patent/MA52680A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Dans divers modes de réalisation, la présente invention concerne des méthodes de diagnostic d'un besoin de revascularisation artérielle périphérique et/ou de réduction d'un besoin de revascularisation artérielle périphérique chez un sujet par l'administration au sujet d'une composition pharmaceutique comprenant d'environ 1 g à environ 4 g d'un ester éthylique de l'acide eicosapentaénoïque ou d'un dérivé de celui-ci.
MA52680A 2018-08-17 2019-08-15 Méthodes de réduction du besoin de revascularisation artérielle périphérique chez un sujet traité par des statines MA52680A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862719404P 2018-08-17 2018-08-17
PCT/US2019/046710 WO2020037153A1 (fr) 2018-08-17 2019-08-15 Méthodes de réduction du besoin de revascularisation artérielle périphérique chez un sujet traité par des statines

Publications (1)

Publication Number Publication Date
MA52680A1 true MA52680A1 (fr) 2021-11-30

Family

ID=69524891

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52680A MA52680A1 (fr) 2018-08-17 2019-08-15 Méthodes de réduction du besoin de revascularisation artérielle périphérique chez un sujet traité par des statines

Country Status (17)

Country Link
US (2) US20220362200A1 (fr)
EP (1) EP3836914A4 (fr)
JP (1) JP2021534185A (fr)
KR (1) KR20210047312A (fr)
CN (1) CN112912071A (fr)
AU (2) AU2019321568B2 (fr)
BR (1) BR112021002884A2 (fr)
CL (3) CL2021000400A1 (fr)
EA (1) EA202190547A1 (fr)
IL (1) IL280643A (fr)
MA (1) MA52680A1 (fr)
MX (1) MX2021001906A (fr)
NI (1) NI202100009A (fr)
PH (1) PH12021550328A1 (fr)
SG (1) SG11202101562UA (fr)
TN (1) TN2021000028A1 (fr)
WO (1) WO2020037153A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (fr) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (fr) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (fr) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Procédés de réduction ou de prévention de l'oxydation des ldl petites et denses ou des acides gras polyinsaturés membranaires
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US12430998B2 (en) 2018-09-14 2025-09-30 Avive Solutions, Inc. Device based responder network activation and virtual assistant integration
US11640755B2 (en) 2018-09-14 2023-05-02 Avive Solutions, Inc. Real time defibrillator incident data
US11645899B2 (en) 2018-09-14 2023-05-09 Avive Solutions, Inc. Responder network
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (fr) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Procedes de reduction du risque d'evenements cardiovasculaires chez un sujet souffrant d'une fibrillation auriculaire et/ou d'un flutter auriculaire
US20210153817A1 (en) * 2019-11-21 2021-05-27 Avive Solutions, Inc. Device based responder network activation and virtual assistant integration
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4329742A4 (fr) * 2021-04-29 2025-02-26 Amarin Pharmaceuticals Ireland Limited Compositions comprenant epa et leurs méthodes d'utilisation pour traiter et/ou prévenir un dysfonctionnement endothélial chez un sujet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239927A1 (en) * 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
JP2009544701A (ja) * 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
US9603826B2 (en) * 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
CN114558129A (zh) * 2014-03-17 2022-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
US10406130B2 (en) * 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
PT3275438T (pt) * 2016-07-29 2021-01-25 Kowa Co Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual

Also Published As

Publication number Publication date
PH12021550328A1 (en) 2021-10-04
CA3109774A1 (fr) 2020-02-20
AU2019321568B2 (en) 2025-01-30
SG11202101562UA (en) 2021-03-30
CN112912071A (zh) 2021-06-04
CL2021003222A1 (es) 2022-07-22
CL2021000400A1 (es) 2021-07-02
TN2021000028A1 (en) 2022-10-03
NI202100009A (es) 2021-06-22
EP3836914A4 (fr) 2022-05-18
EA202190547A1 (ru) 2021-04-27
BR112021002884A2 (pt) 2021-05-11
EP3836914A1 (fr) 2021-06-23
KR20210047312A (ko) 2021-04-29
JP2021534185A (ja) 2021-12-09
US20220362200A1 (en) 2022-11-17
IL280643A (en) 2021-03-25
AU2019321568A1 (en) 2021-03-11
WO2020037153A1 (fr) 2020-02-20
CL2021003221A1 (es) 2022-07-22
AU2025202801A1 (en) 2025-05-08
MX2021001906A (es) 2021-04-28
AU2025202801A9 (en) 2026-03-05
US20250186386A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
EA202190547A1 (ru) Способы снижения потребности в реваскуляризации периферических артерий у субъекта, получающего лечение статинами
CA3156676A1 (fr) Micro-aiguilles a base de fibroine de soie et leurs utilisations
MA57908B1 (fr) Composés macrocycliques substitués et méthodes de traitement associées
CL2023000767A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
MA50258B2 (fr) Procédés de réduction du risque d'un événement cardiovasculaire chez un sujet soumis à un traitement par une statine
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
Louboutin et al. Role of oxidative stress in HIV-1-associated neurocognitive disorder and protection by gene delivery of antioxidant enzymes
WO2019051122A3 (fr) Fractions de liaison à activation conditionnelle contenant des régions fc
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
Chien et al. The effects of two Nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy
AR044337A1 (es) Procedimiento para potenciar la cognicion usando ziprasidona
MA41150B1 (fr) Polymères de liaison aux protons pour administration orale
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
WO2019018451A3 (fr) Compositions et méthodes de prévention et de traitement d'effets de proximité induits par rayonnement provoqués par un rayonnement ou une radiothérapie
KR960033452A (ko) 시신경 질환의 치료를 위한 프로스타노산 화합물
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
MA39421A (fr) Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes
MX9304503A (es) Compuestos antiinflamatorios.
MA58093B1 (fr) Nouveaux analogues d'insuline et leurs utilisations
MA40937A (fr) Acide benzoïque, dérivés d'acide benzoïque et conjugués d'acide hétéroarylcarboxylique d'oxymorphone, promédicaments, leurs procédés de fabrication et d'utilisation
MA45202A1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
MA60150A1 (fr) Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
MA47498B1 (fr) Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal